Poop pills could tame HIV inflammation
NCT ID NCT06022406
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether taking capsules containing healthy donor stool (fecal microbiota transplantation, or FMT) can reduce gut inflammation in people with HIV who are on antiretroviral therapy (ART) but have a low CD4/CD8 ratio. Twenty participants were randomly assigned to receive either FMT or placebo capsules twice, three weeks apart. Researchers measured changes in gut permeability and inflammation markers in the blood and, in a substudy, in colon biopsies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fecal microbiota transplantation (FMT) capsules
What this could lead to
If it works, this could point toward a way to reduce chronic inflammation in people with HIV, potentially lowering the risk of long-term health problems.
What could go wrong
This is a very small, early pilot study with only 20 participants. The treatment may not reduce inflammation, and the effects may not be lasting or generalizable to all people with HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chronic Viral Illness Service
Montreal, Quebec, H4A 3J1, Canada